The Effect of Buprenorphine Delivered by Buprenorphine Transdermal System (BTDS) at Doses up to 80 Micrograms/Hour (mcg/hr) and Naltrexone on Electrocardiogram (ECG) Intervals in Healthy Volunteers

Inclusion Criteria: * Provide written informed consent. * Males and females aged 18 to 55, inclusive. * Body weight ranging from 50 to 100 kilograms (kg) (110 to 220 lbs) and body mass index (BMI) ranging from 18 to 30 (kg/m2), inclusive. * Healthy and free of significant abnormal findings as determined by medical history, physical examination, clinical laboratory values, vital signs, and resting 12-lead ECG. * Females of child-bearing potential must be using an adequate and reliable method of contraception (ie, barrier with additional spermicidal foam or jelly, intra-uterine device, hormonal contraception). Females who are postmenopausal must have been postmenopausal ≥ 1 year and have elevated serum follicle stimulating hormone (FSH). * Willing to eat the food supplied during the study. * Willing to refrain from strenuous exercise during the entire study. Subjects will not begin a new exercise program nor participate in any unusually strenuous physical exertion. * All 8 anatomical transdermal system (TDS) application sites (upper back, upper chest, upper outer arm, or lateral thorax) must be acceptable for study use. Exclusion Criteria: * Females who are pregnant (positive beta human chorionic gonadotropin test) or lactating. * Current or recent (within 5 years) history of drug or alcohol abuse. * History or any current conditions that might interfere with drug absorption (transdermal or gastrointestinal), distribution, metabolism or excretion. * Use of an opioid-containing medication in the past 30 days preceding the initial dose in this study. * Known allergy to buprenorphine, any excipient of BTDS, opioids, psychotropic or hypnotic drugs, and/or moxifloxacin or any member of the quinolone class drugs. * Any history of frequent nausea or emesis regardless of etiology. * Any history of seizures or head trauma with sequelae. * Participation in a clinical drug study during the 30 days preceding the initial dose in this study. * Any significant illness during the 30 days preceding the initial dose in this study. * Use of any medication including thyroid hormonal therapy (hormonal contraception and hormonal replacement therapy in the form of estrogen with or without progestin is allowed), vitamins, herbal and/or mineral supplements during the 7 days preceding the initial dose. * Any personal or family history of prolonged QT interval or disorders of cardiac rhythm. * Abnormal cardiac conditions including hypertension. * Abnormal cardiac condition denoted by any of the following: * QTcF interval \> 450 milliseconds (msec) * PR interval \> 240 msec or QRS \> 110 msec * Evidence of second- or third-degree atrioventricular (AV) block * Pathological Q-waves (defined as Q-wave \>40 msec or depth \> 0.5 mV) * Evidence of ventricular pre-excitation, complete left bundle branch block, right bundle branch block (RBBB), or incomplete RBBB * With a resting heart rate outside the range of 45 to 85 beats per minute (bpm) * Abnormalities on physical examination, vital signs, ECG, or clinical laboratory values, unless those abnormalities were judged clinically insignificant by the investigator. * Oxygen saturation (SpO2) ≤ 94% as measured by pulse oximetry. * Refusal to abstain from caffeine or xanthine containing beverages entirely during confinement. * Refusal to abstain from consumption of alcoholic beverages 48 hours prior to initial study drug administration and any time during study. * History of smoking or use of nicotine products within 45 days of study drug administration or a positive urine cotinine test * Blood or blood products donated within 30 days prior to study drug administration or anytime during the study. * Positive results of urine drug screen or alcohol screen. * Positive results of hepatitis B surface antigen (HBsAg), hepatitis C antibody (anti-HCV). * Positive naloxone challenge test. * Presence of Gilbert's Syndrome, or any known hepatobiliary abnormalities. * The investigator believes the subject to be unsuitable for reason(s) not specifically stated in the exclusion criteria. * Subjects who have allergies or other contraindications to transdermal systems or patch adhesives. * Clinically significant history of allergic reaction to wound dressings or elastoplast. * Subjects with a dermatological disorder at any relevant patch application site that precludes proper placement and/or rotation of patch. * Taking antihistamines within 72 hours prior to dosing or systemic or topical corticosteroids within 3 weeks prior to dosing. * Subjects will not allow hair to be removed at the proposed patch application site which may prevent proper placement of the patch. * Subjects for whom a proper assessment of possible application site reactions would be confounded by local skin conditions.